Q4 2024 EPS Estimates for MiMedx Group, Inc. (NASDAQ:MDXG) Decreased by HC Wainwright

MiMedx Group, Inc. (NASDAQ:MDXG) – Stock analysts at HC Wainwright dropped their Q4 2024 earnings per share estimates for shares of MiMedx Group in a research note issued on Wednesday, May 1st. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings of $0.11 per share for the quarter, down from their previous estimate of $0.12. HC Wainwright has a “Buy” rating and a $11.00 price objective on the stock. The consensus estimate for MiMedx Group’s current full-year earnings is $0.32 per share.

Several other research analysts also recently commented on the company. StockNews.com downgraded MiMedx Group from a “strong-buy” rating to a “buy” rating in a report on Friday. Mizuho lifted their target price on MiMedx Group from $13.00 to $14.00 and gave the stock a “buy” rating in a report on Friday, March 1st. Finally, Lake Street Capital assumed coverage on MiMedx Group in a research note on Thursday, March 7th. They issued a “buy” rating and a $12.00 price objective on the stock. Five investment analysts have rated the stock with a buy rating, According to MarketBeat, MiMedx Group currently has a consensus rating of “Buy” and a consensus price target of $12.25.

MiMedx Group Stock Down 1.7 %

Shares of MDXG opened at $7.37 on Thursday. The company has a market capitalization of $1.09 billion, a PE ratio of 16.75 and a beta of 1.44. MiMedx Group has a 12 month low of $5.13 and a 12 month high of $9.27. The stock’s 50-day moving average price is $7.36 and its two-hundred day moving average price is $7.56. The company has a current ratio of 3.29, a quick ratio of 3.11 and a debt-to-equity ratio of 0.12.

MiMedx Group (NASDAQ:MDXG) last announced its earnings results on Wednesday, February 28th. The company reported $0.04 EPS for the quarter, missing the consensus estimate of $0.08 by ($0.04). The company had revenue of $86.83 million for the quarter, compared to analyst estimates of $85.58 million. MiMedx Group had a return on equity of 39.42% and a net margin of 18.63%.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. grew its stake in shares of MiMedx Group by 4.1% during the 3rd quarter. Vanguard Group Inc. now owns 6,437,155 shares of the company’s stock worth $46,927,000 after acquiring an additional 250,812 shares during the period. Cannell Capital LLC grew its stake in shares of MiMedx Group by 9.1% during the 4th quarter. Cannell Capital LLC now owns 2,480,969 shares of the company’s stock worth $21,758,000 after acquiring an additional 207,207 shares during the period. Charles Schwab Investment Management Inc. grew its stake in shares of MiMedx Group by 5.4% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,134,213 shares of the company’s stock worth $9,947,000 after acquiring an additional 57,704 shares during the period. EAM Investors LLC grew its stake in shares of MiMedx Group by 20.9% during the 3rd quarter. EAM Investors LLC now owns 664,213 shares of the company’s stock worth $4,842,000 after acquiring an additional 114,880 shares during the period. Finally, Russell Investments Group Ltd. grew its stake in shares of MiMedx Group by 1,577.5% during the 4th quarter. Russell Investments Group Ltd. now owns 525,059 shares of the company’s stock worth $4,605,000 after acquiring an additional 493,759 shares during the period. Institutional investors own 79.15% of the company’s stock.

Insider Buying and Selling at MiMedx Group

In other news, CAO William Frank Iv Hulse sold 20,381 shares of the firm’s stock in a transaction dated Wednesday, March 13th. The stock was sold at an average price of $7.95, for a total value of $162,028.95. Following the completion of the sale, the chief accounting officer now directly owns 479,959 shares in the company, valued at approximately $3,815,674.05. The sale was disclosed in a document filed with the SEC, which is accessible through this link. In related news, COO Ricci S. Whitlow sold 15,271 shares of the stock in a transaction on Tuesday, February 20th. The stock was sold at an average price of $8.01, for a total value of $122,320.71. Following the completion of the sale, the chief operating officer now directly owns 401,050 shares of the company’s stock, valued at approximately $3,212,410.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CAO William Frank Iv Hulse sold 20,381 shares of the stock in a transaction on Wednesday, March 13th. The shares were sold at an average price of $7.95, for a total value of $162,028.95. Following the completion of the sale, the chief accounting officer now directly owns 479,959 shares of the company’s stock, valued at $3,815,674.05. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 51,145 shares of company stock valued at $409,378. Corporate insiders own 19.90% of the company’s stock.

About MiMedx Group

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.